Research programme: stromal vascular fraction cell therapies - IntelliCell BioSciences

Drug Profile

Research programme: stromal vascular fraction cell therapies - IntelliCell BioSciences

Alternative Names: Adult autologous vascular fraction cells - Intellicell Biosciences; SVFC - Intellicell Biosciences

Latest Information Update: 06 Aug 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator IntelliCell BioSciences
  • Developer IntelliCell BioSciences; University of Arizona
  • Class Cell therapies; Stem cell therapies
  • Mechanism of Action Cell replacements; Stem cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Heart failure; Osteoarthritis

Most Recent Events

  • 01 Aug 2014 IntelliCell Biosciences files a pre-IND with the US FDA for Osteoarthritis (knee)
  • 29 Apr 2014 Preclinical trials in Heart failure in USA (IV)
  • 29 Apr 2014 Preclinical trial for Heart failure in USA (Intramyocardial)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top